This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
by David Borun
Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.
Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View
by Zacks Equity Research
Ligand (LGND) beats both earnings and sales estimates in the first quarter of 2018. The company repeats its previous guidance for 2018.
What's in Store for Radius Health (RDUS) in Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the uptake of lead drug, Tymlos, and other pipeline developments when Radius Health (RDUS) reports results for the first quarter.
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.
The Zacks Analyst Blog Highlights: Apple, ExxonMobil, Citigroup and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, ExxonMobil, Citigroup and Amgen
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.
Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
by Zacks Equity Research
Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.
Company News for Apr 26, 2018
by Zacks Equity Research
Companies In The News are: ANTM,VIAB,F,AMGN
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.
What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
by Zacks Equity Research
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.
Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
by Zacks Equity Research
Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
Novartis Announces Data on Cardiovascular Drug Entresto
by Zacks Equity Research
Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.
Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
by Zacks Equity Research
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
by Zacks Equity Research
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.